TY - JOUR
T1 - Potent neutralization by antibodies targeting the MPXV A28 protein
AU - Yefet, Ron
AU - Battini, Leandro
AU - Hubert, Mathieu
AU - Rakayev, Katya
AU - Guivel-Benhassine, Florence
AU - Rattner, Noam
AU - Porrot, Francoise
AU - Abramovitz, Lilach
AU - Ostashinsky, Gilad
AU - Ben-Shalom, Noam
AU - Postal, Jeanne
AU - Polonsky, Ksenia
AU - Ralph-Altman, Maya
AU - Sweed, Sireen
AU - Korner, Tal
AU - Friedel, Nadav
AU - Hagin, David
AU - Sprecher, Eli
AU - Fishelson, Zvi
AU - Kobiler, Oren
AU - Adler-Abramovich, Lihi
AU - Schwartz, Olivier
AU - Guardado-Calvo, Pablo
AU - Freund, Natalia T.
N1 - Publisher Copyright:
© The Author(s) 2025.
PY - 2025/12
Y1 - 2025/12
N2 - Monkeypox virus (MPXV) is the most pathogenic Poxvirus in circulation, yet key viral antigens remain immunologically unexplored. We isolate and characterize a panel of monoclonal antibodies (mAbs) targeting MPXV A28 (OPG153), an important membranal protein present on mature MPXV virions. From male convalescent individuals, we isolate anti-A28 mAbs alongside additional mAbs targeting the A35 and H3 proteins. Anti-A28 mAbs potently neutralize MPXV and Vaccinia virus (VACV) through complement-dependent mechanisms involving C1q and C3 deposition. High-resolution crystal structures of two anti-A28 mAbs, 10M2146 and 8M2110, in complex with VACV A26 reveal two distinct and highly conserved proximal epitopes within the N-terminal domain. Passive transfer of 8M2110 modestly attenuates disease in infected female mice. Moreover, immunization with A28 elicits antigen-specific B cells and robust neutralizing antibody responses and provides protection against lethal VACV challenge. These findings identify MPXV A28 as a promising central target for the induction of neutralizing antibodies and antiviral interventions.
AB - Monkeypox virus (MPXV) is the most pathogenic Poxvirus in circulation, yet key viral antigens remain immunologically unexplored. We isolate and characterize a panel of monoclonal antibodies (mAbs) targeting MPXV A28 (OPG153), an important membranal protein present on mature MPXV virions. From male convalescent individuals, we isolate anti-A28 mAbs alongside additional mAbs targeting the A35 and H3 proteins. Anti-A28 mAbs potently neutralize MPXV and Vaccinia virus (VACV) through complement-dependent mechanisms involving C1q and C3 deposition. High-resolution crystal structures of two anti-A28 mAbs, 10M2146 and 8M2110, in complex with VACV A26 reveal two distinct and highly conserved proximal epitopes within the N-terminal domain. Passive transfer of 8M2110 modestly attenuates disease in infected female mice. Moreover, immunization with A28 elicits antigen-specific B cells and robust neutralizing antibody responses and provides protection against lethal VACV challenge. These findings identify MPXV A28 as a promising central target for the induction of neutralizing antibodies and antiviral interventions.
UR - https://www.scopus.com/pages/publications/105026210180
U2 - 10.1038/s41467-025-66344-0
DO - 10.1038/s41467-025-66344-0
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 41372735
AN - SCOPUS:105026210180
SN - 2041-1723
VL - 16
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 11455
ER -